BRAF mutations and the association of V600E with CD133 and CDX2 expression in a Pakistani colorectal carcinoma cohort

Abstract Background Despite a high incidence of colorectal carcinoma, data regarding genetic aberrations in colorectal carcinoma (CRC) patients in Pakistan is scarce. This study aimed to determine the frequency of BRAFV600E mutations in colorectal carcinoma tissue in the Pakistani population and to...

Full description

Bibliographic Details
Published in:	BMC Cancer
Main Authors:	Sobia Hassan, Talat Mirza, Ambrina Khatoon, Uzma Bukhari, Fouzia Shaikh, Asad Karim
Format:	Article
Language:	English
Published:	BMC 2024-09-01
Subjects:	Colon cancer Genetic Polymorphism Prominin-1 Cancer stem cells Vemurafenib
Online Access:	https://doi.org/10.1186/s12885-024-12925-z

Similar Items

Durable Remission After Targeted Therapy in BRAF V600E–Mutant Metastatic Colorectal Cancer: Case Report
by: Daniel A. Fox, et al.
Published: (2025-01-01)

Secretome Screening of BRAFV600E-Mutated Colon Cancer Cells Resistant to Vemurafenib
by: Iris Car, et al.
Published: (2023-04-01)

DNA alterations in Cd133+ and Cd133- tumour cells enriched from intra-operative human colon tumour biopsies
by: Diana Cervantes-Madrid, et al.
Published: (2017-03-01)

Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution
by: Vincenzo Di Nunno, et al.
Published: (2023-01-01)

Improvement of Neurodegenerative Disease after Use of Vemurafenib in Refractory BRAF V600E-Mutated Langerhans Cell Histiocytosis: A Case Report
by: Young Kwon Koh, et al.
Published: (2022-10-01)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
by: Francesca Del Bufalo, et al.
Published: (2018-11-01)

Prom1 function in development, intestinal inflammation, and intestinal tumorigenesis
by: Baktiar Omer Karim, et al.
Published: (2014-11-01)

Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study
by: Yuankai Shi, et al.
Published: (2024-06-01)

The Impact of Glycosylation on the Functional Activity of CD133 and the Accuracy of Its Immunodetection
by: Alisa Gisina, et al.
Published: (2024-06-01)

COP1 Deficiency in BRAF<sup>V600E</sup> Melanomas Confers Resistance to Inhibitors of the MAPK Pathway
by: Ada Ndoja, et al.
Published: (2025-06-01)

In vitro characterization of CD133lo cancer stem cells in Retinoblastoma Y79 cell line
by: Rohini M. Nair, et al.
Published: (2017-11-01)

Pharmacoeconomic analysis of vemurafenib and dabrafenib use in patients with inoperable or metastatic melanoma with BRAF V600 mutation
by: A. S. Kolbin, et al.
Published: (2018-05-01)

Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
by: Tiziana Notarangelo, et al.
Published: (2017-10-01)

Treating malignant melanoma when a rare BRAF V600M mutation is present: case report and literature review
by: Popescu Andrei, et al.
Published: (2018-06-01)

Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
by: Lu Si, et al.
Published: (2018-05-01)

Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma
by: Azad Saei, et al.
Published: (2018-09-01)

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
by: Matthias Lang, et al.
Published: (2023-03-01)

Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation
by: Fedor V. Moiseyenko, et al.
Published: (2019-05-01)

Targeting prominin2 transcription to overcome ferroptosis resistance in cancer
by: Caitlin W Brown, et al.
Published: (2021-07-01)

Unusual Skin Carcinomas Induced by BRAF Inhibitor for Metastatic Melanoma: A Case Report
by: Stefano Cavalieri, et al.
Published: (2017-07-01)

Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study
by: Pópulo H, et al.
Published: (2021-05-01)

In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors
by: Teresa Żołek, et al.
Published: (2023-07-01)

Commentary: Could We Address the Interplay Between CD133, Wnt/β-Catenin, and TERT Signaling Pathways as a Potential Target for Glioblastoma Therapy?
by: Christine A. Fargeas, et al.
Published: (2021-08-01)

Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells
by: Carlotta Guzzetti, et al.
Published: (2023-09-01)

All-Trans Retinoic Acid Fosters the Multifarious U87MG Cell Line as a Model of Glioblastoma
by: Markéta Pokorná, et al.
Published: (2021-06-01)

BRAF inhibition with concomitant tumor treating fields for a multiply progressive pleomorphic xanthoastrocytoma
by: Rimas V Lukas, et al.
Published: (2018-04-01)

PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas
by: Junling Shen, et al.
Published: (2022-08-01)

Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma
by: Byung-Sun Park, et al.
Published: (2024-07-01)

Inhibitors of pan PI3K signaling synergize with BRAF or MEK inhibitors to prevent BRAF-mutant melanoma cell growth
by: Melanie eSweetlove, et al.
Published: (2015-06-01)

Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits
by: Jiaojiao Hao, et al.
Published: (2019-02-01)

PROM2 overexpression induces metastatic potential through epithelial‐to‐mesenchymal transition and ferroptosis resistance in human cancers
by: Justine Paris, et al.
Published: (2024-03-01)

Vemurafenib Induces Senescent Phenotype with Increased Adhesion in BRAF Mutant A375 but not in Wild Type BRAF SK-MEL-2 Melanoma Cells
by: Aleksandra Rashidovna Esimbekova, et al.
Published: (2025-04-01)

Deletion of prominin-1 in mice results in disrupted photoreceptor outer segment protein homeostasis
by: Yu-Shu Xiao, et al.
Published: (2021-09-01)

Bilirubin Restrains the Anticancer Effect of Vemurafenib on BRAF-Mutant Melanoma Cells Through ERK-MNK1 Signaling
by: Yufan Tan, et al.
Published: (2021-06-01)

Characterization of two melanoma cell lines resistant to BRAF/MEK inhibitors (vemurafenib and cobimetinib)
by: Magdalena Kot, et al.
Published: (2024-08-01)

Extracellular vesicles promote migration despite BRAF inhibitor treatment in malignant melanoma cells
by: Afrodité Németh, et al.
Published: (2024-05-01)

Acquired and intrinsic resistance to vemurafenib in BRAFV600E‐driven melanoma brain metastases
by: Ping Zhang, et al.
Published: (2024-01-01)

Triple-Regimen of Vemurafenib, Irinotecan, and Cetuximab for the Treatment of BRAFV600E-Mutant CRC: A Case Report and Review
by: Su Min Cho, et al.
Published: (2021-12-01)

Ferroptosis resistance mediated by exosomal release of iron
by: Caitlin W. Brown, et al.
Published: (2020-05-01)

Targeted therapy with BRAF inhibitor Vemurafenib in relapse/refractory multisystem langerhans cell-retrospective analysis from a tertiary care center in India
by: Purva Kanvinde, et al.
Published: (2021-12-01)